

Resource Summary Report

Generated by RRID on Jul 28, 2026

PerCP/Cyanine5.5 anti-human CD279 (PD-1)

RRID:AB_1595461

Type: Antibody

Proper Citation

BioLegend Cat# 329914, RRID:AB_1595461

Antibody Information

URL: http://antibodyregistry.org/AB_1595461

Proper Citation: BioLegend Cat# 329914, RRID:AB_1595461

Target Antigen: CD279

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: PerCP/Cyanine5.5 anti-human CD279 (PD-1)

Description: This monoclonal targets CD279

Target Organism: human

Clone ID: Clone EH12.2H7

Antibody ID: AB_1595461

Vendor: BioLegend

Catalog Number: 329914

Alternative Catalog Numbers: 329913

Record Creation Time: 20250819T205123+0000

Record Last Update: 20250819T210252+0000

Ratings and Alerts

- Used for flow cytometry assay by the Human Islet Research Network community.
Contact(s): [Megan Sykes](#) - Human Islets Research Network <https://hirnetwork.org/>

No alerts have been found for PerCP/Cyanine5.5 anti-human CD279 (PD-1).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 5 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Cook MS, et al. (2025) CAR-T cells containing CD28 versus 4-1BB co-stimulatory domains show distinct metabolic profiles in patients. Cell reports, 44(7), 115973.

Pan Q, et al. (2023) Phase 1 clinical trial to assess safety and efficacy of NY-ESO-1-specific TCR T cells in HLA-A*02:01 patients with advanced soft tissue sarcoma. Cell reports. Medicine, 4(8), 101133.

Wu HL, et al. (2023) Allogeneic immunity clears latent virus following allogeneic stem cell transplantation in SIV-infected ART-suppressed macaques. Immunity, 56(7), 1649.

Jenkins BJ, et al. (2023) Canagliflozin impairs T cell effector function via metabolic suppression in autoimmunity. Cell metabolism, 35(7), 1132.

Chow A, et al. (2023) The ectonucleotidase CD39 identifies tumor-reactive CD8+ T cells predictive of immune checkpoint blockade efficacy in human lung cancer. Immunity, 56(1), 93.